A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
Clinical trial NCT06067230 · COMPLETED
Trial details
- NCT number
- NCT06067230
- Sponsor
- ModernaTX, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-06
- Primary completion
- 2026-07-24
- Enrollment
- 1153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.